AAVantgarde is a clinical stage, ophthalmology company advancing best-in-class therapies for patients with inherited retinal diseases, starting with Usher 1B and Stargardt Disease. The technology platform at AAVantgarde enables gene replacement of large genes that exceed the capacity of traditional gene therapy vectors. Headquartered in Italy, AAVantgarde was founded by Professor Alberto Auricchio, a highly recognized scientist and a pioneer in the field of gene therapy.
